Photobiomodulation Therapy is Able to Modulate PGE₂ Levels in Patients With Chronic Non-Specific Low Back Pain: A...

Area of Science:

• Biomedical Engineering
• Pain Management
• Rehabilitation Medicine

Background:

• Non-specific low back pain (LBP) is associated with elevated inflammatory biomarkers.
• Photobiomodulation therapy (PBMT) is a potential therapeutic approach for LBP.
• PBMT may reduce pain by modulating inflammatory mediators.

Purpose of the Study:

• To evaluate the effects of PBMT versus placebo on inflammatory mediators and pain in chronic non-specific LBP patients.
• To assess changes in prostaglandin E2, tumor necrosis factor-α, and interleukin-6 levels.
• To measure pain intensity changes post-treatment.

Main Methods:

• Randomized, triple-blinded, placebo-controlled trial.
• Eighteen patients with chronic non-specific LBP were enrolled.
• A single session of active or placebo PBMT was administered, with outcomes measured pre- and post-treatment.

Main Results:

• PBMT significantly decreased prostaglandin E2 levels compared to placebo (mean difference: -1470 pg/ml).
• No significant differences were observed in tumor necrosis factor-α, interleukin-6, or pain intensity between groups.
• No adverse events were reported by patients.

Conclusions:

• PBMT demonstrated the ability to modulate prostaglandin E2 levels in LBP patients.
• This modulation of prostaglandin E2 may contribute to the analgesic effects of PBMT.
• PBMT shows promise as a treatment for chronic non-specific LBP.